Harvard Catalyst Profiles
Contact, publication, and social network information about Harvard faculty and fellows.
Open Source Software
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
Return to Top
Search Result Details
Back to Search Results
This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Epigenetic reprogramming in cancer.
A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force.
Comparison of sequencing-based methods to profile DNA methylation and identification of monoallelic epigenetic modifications.
The NIH Roadmap Epigenomics Mapping Consortium.
Transcriptional and epigenetic dynamics during specification of human embryonic stem cells.
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.
SAM domain polymerization links subnuclear clustering of PRC1 to gene silencing.
An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Dissecting neural differentiation regulatory networks through epigenetic footprinting.
Integrative analysis of 111 reference human epigenomes.
Genetic and epigenetic fine mapping of causal autoimmune disease variants.
Notch-mediated expansion of cord blood progenitors: maintenance of transcriptional and epigenetic fidelity.
Production sequencing of reference human epigenomes
Epigenetic plasticity in tumor initiation and evolution
A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression.
Epigenetic plasticity and the hallmarks of cancer.
Single-cell and single-molecule epigenomics to uncover genome regulation at unprecedented resolution.
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL.
Single-cell lineage analysis reveals genetic and epigenetic interplay in glioblastoma drug resistance.